Literature DB >> 10878391

Determination of carrier status for the Wiskott-Aldrich syndrome by flow cytometric analysis of Wiskott-Aldrich syndrome protein expression in peripheral blood mononuclear cells.

M Yamada1, T Ariga, N Kawamura, K Yamaguchi, M Ohtsu, D L Nelson, T Kondoh, I Kobayashi, M Okano, K Kobayashi, Y Sakiyama.   

Abstract

The Wiskott-Aldrich syndrome (WAS) is caused by defects in the WAS protein (WASP) gene on the X chromosome. Previous study disclosed that flow cytometric analysis of intracellular WASP expression (FCM-WASP analysis) in lymphocytes was useful for the diagnosis of WAS patients. Lymphocytes from all WAS patients showed WASPdim instead of WASPbright. Here we report that FCM-WASP analysis in monocytes could be a useful tool for the WAS carrier diagnosis. Monocytes from all nine WAS carriers showed varied population of WASPdim together with WASPbright. None of control individuals possessed the WASPdim population. In contrast, lymphocytes from all the carriers except two lacked the WASPdim population. The difference of the WASPdim population in monocytes and lymphocytes observed in WAS carriers suggests that WASP plays a more critical role in the development of lymphocytes than in that of monocytes. The present studies suggest that a skewed X-chromosomal inactivation pattern observed in WAS carrier peripheral blood cells is not fixed at the hemopoietic stem cell level but progresses after the lineage commitment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878391     DOI: 10.4049/jimmunol.165.2.1119

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome.

Authors:  Eun-Kyeong Jo; Takeshi Futatani; Hirokazu Kanegane; Takeo Kubota; Young-Ho Lee; Jin-A Jung; Chang-Hwa Song; Jeong-Kyu Park; Shigeaki Nonoyama; Toshio Miyawaki
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

2.  Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism.

Authors:  T Wada; S H Schurman; M Otsu; E K Garabedian; H D Ochs; D L Nelson; F Candotti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia.

Authors:  Hirozumi Sano; Ryoji Kobayashi; Daisuke Suzuki; Kazue Yasuda; Masanori Nakanishi; Tetsuro Nagashima; Masafumi Yamada; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2012-06-27       Impact factor: 2.490

Review 4.  Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment.

Authors:  Sung-Yun Pai; Luigi D Notarangelo
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

5.  Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.

Authors:  Francesco Marangoni; Marita Bosticardo; Sabine Charrier; Elena Draghici; Michela Locci; Samantha Scaramuzza; Cristina Panaroni; Maurilio Ponzoni; Francesca Sanvito; Claudio Doglioni; Marie Liabeuf; Bernard Gjata; Marie Montus; Katherine Siminovitch; Alessandro Aiuti; Luigi Naldini; Loïc Dupré; Maria Grazia Roncarolo; Anne Galy; Anna Villa
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

6.  Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: a review of case-based examples of selected immunodeficiencies.

Authors:  Roshini S Abraham
Journal:  Clin Mol Allergy       Date:  2011-04-09

Review 7.  Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments.

Authors:  David Buchbinder; Diane J Nugent; Alexandra H Fillipovich
Journal:  Appl Clin Genet       Date:  2014-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.